Literature DB >> 28993394

Recruitment, adherence, and retention of endometrial cancer survivors in a behavioural lifestyle programme: the Diet and Exercise in Uterine Cancer Survivors (DEUS) parallel randomised pilot trial.

Dimitrios A Koutoukidis1,2, Rebecca J Beeken2,3, Ranjit Manchanda1,4,5, Moscho Michalopoulou1, Matthew Burnell1, M Tish Knobf1,6, Anne Lanceley1.   

Abstract

OBJECTIVE: Healthy eating and physical activity may help endometrial cancer survivors (ECS) improve their quality of life. However, most ECS do not meet the relevant guidelines. This pilot trial aimed to test the study feasibility procedures for a definitive trial of a behavioural lifestyle programme. DESIGN AND
SETTING: This 24-week parallel two-arm randomised pilot trial took place in two hospitals in London, UK (April 2015-June 2016). PARTICIPANTS: Sixty disease-free ECS within 3 years of diagnosis.
INTERVENTIONS: Participants were randomised using minimisation to receive the intervention or care as usual. The 'Shape-Up following cancer treatment' programme used self-monitoring, goal-setting, self-incentives, problem-solving and group social support for 12 hours over 8 weeks to help survivors improve their eating and physical activity. OUTCOME MEASURES: The main outcome measures were recruitment, adherence, and retention rates. Further outcomes included barriers to participation and feedback on programme satisfaction.
RESULTS: Of the 296 potentially eligible ECS, 20% (n=60) were randomly allocated to the active intervention (n=29) or control group (n=31). Three participants in each arm were deemed ineligible after randomisation and excluded from analysis. Twenty participants (77%; 95% CI 61% to 93%) adhered to the intervention and provided generally favourable feedback. At 24 weeks, 25/26 (96%; 95% CI 89% to 100%) intervention and 24/28 (86%; 95% CI 73% to 99%) control participants completed their assessment. No intervention-related adverse events were reported. Among eligible survivors who declined study participation (n=83), inconvenience (78%; 95% CI 69% to 87%) was the most common barrier.
CONCLUSIONS: The trial was feasible to deliver based on the a priori feasibility criteria. Enhancing recruitment and adherence in a definitive trial will require designs that promote convenience and consider ECS-reported barriers. TRIAL REGISTRATION NUMBER: NCT02433080; Pre-results. TRIAL FUNDING: University College London, St. Bartholomew's Hospital Nurses League, and NIHR University College London Hospitals Biomedical Research Centre. © Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

Entities:  

Keywords:  Endometrial cancer; behaviour change; healthy eating; intervention; physical activity; survivorship

Mesh:

Year:  2017        PMID: 28993394      PMCID: PMC5640120          DOI: 10.1136/bmjopen-2017-018015

Source DB:  PubMed          Journal:  BMJ Open        ISSN: 2044-6055            Impact factor:   2.692


This trial tested the feasibility of a standardised theory-based behavioural lifestyle programme for endometrial cancer survivors using a robust randomised parallel design. Barriers to participation were systematically assessed. The study aimed to minimise these barriers by recruiting survivors within the ‘teachable moment’ period and capitalising on the endorsement of the study from their clinicians. The small sample size and recruitment from London-based hospitals limit the generalisability of the outcomes.

Introduction

Endometrial cancer is the most common gynaecological cancer with about 455 000 incident cases worldwide in 2015. It affects mostly women in developed countries1 and about 75% women will live for more than 10 years after diagnosis.2 They are the cancer group with the highest comorbidity burden among survivors3 and are most likely to die from cardiovascular disease.4 Furthermore, the prevalence of obesity and suboptimal lifestyle behaviours is high, both of which are associated with lower health-related quality of life.5 Although most survivors do not spontaneously adopt health-protective behaviours6 postdiagnosis, they do report trying to make lifestyle changes. However, they experience cancer-specific barriers, such as fatigue and bowel issues, and feel there is a lack of guidance.7 Behavioural lifestyle interventions improve patient-reported outcomes, such as health-related quality of life, in other cancer survivor groups.8–10 Randomised controlled trials (RCTs) in endometrial cancer survivors (ECS) have also shown that health behaviour change is feasible for these patients.11 12 However, the programmes tested to date have been resource-intensive rendering their widespread dissemination challenging. There is, therefore, a need for effective lifestyle behaviour change interventions that can be adopted within the cancer care pathway. We have adapted an existing evidence-based lifestyle intervention,13 which is already running within the healthcare system, to try and facilitate this process.14 The intervention was adapted to the particular needs and preferences of ECS, with patient input and using the intervention mapping approach. A definitive RCT will indicate whether this intervention is effective in promoting long-term behaviour change and improving survivors’ quality of life. This pilot study was conducted to test the feasibility of the planned RCT’s procedures. The primary objective of the pilot trial was therefore to calculate recruitment, adherence, and retention rates. Secondary outcomes included willingness of clinical staff to recruit participants, potential adverse events, barriers to participation, reasons for attrition, and participants’ study experience.15

Methods

Study design and participants

The trial protocol has been published.15 The DEUS (Diet and Exercise in Uterine Cancer Survivors) pilot trial was an 8-week, two-arm, parallel, controlled pilot trial with 1:1 randomisation comparing the use of the ‘Shape-Up following cancer treatment’ programme to care as usual. Women aged ≥18 years who had been diagnosed with endometrial cancer (ICD C54.1) within the previous 36 months were eligible to take part in the study. Women were excluded if (1) they were diagnosed with stage IVB cancer; (2) they were on active anticancer and/or palliative treatment; (3) they had a second primary cancer; (4) they lacked mental capacity to decide to take part in the study and to participate in it; (5) they had severe depression; (6) they were unavailable for longitudinal follow-up assessments; (7) they had participated in a professionally delivered weight loss or exercise programme during the previous 6 months; (8) their performance score was 3–416 (9) or they were unable to understand spoken and written English. At the fifth week of recruitment, the inclusion criterion ‘women willing to attend all sessions’ was removed given the subjective nature of its interpretation and the exclusion criterion ‘women with secondary cancer’ was added to ensure homogeneity.

Recruitment

Potential participants were recruited from the gynaecology outpatient clinics at University College London Hospitals (UCLH) and Barts Health. Interested and potentially eligible participants were introduced to the study by clinicians and researchers attending the clinics as previously described.15 The clinicians at UCLH also identified potential participants that had been treated there but followed up at local sites. Following general practitioner’s verification that the patients were alive, invitation letters signed by the consultant were sent to these women together with the participant information sheet, an opt-in form, a barriers to participation survey and a business reply envelope.

Randomisation and blinding

Consented participants were randomised with a 1:1 allocation to receive either the intervention or usual care through minimisation using age and body mass index (BMI) as stratified variables. The process has been previously described in detail.15 The researcher assessing the 8-week outcomes (MM) was blinded to intervention allocation and participants were requested prior to the assessment not to disclose their allocation.

Shape-Up following cancer treatment intervention

In addition to usual care, intervention-arm participants received the ‘Shape-Up following cancer treatment’ manual and were assigned to groups of three to eight, although the initial plan was that they would be assigned in groups of eight. The allocation to groups was on a first-come, first-served basis to avoid delays in delivering the intervention to randomised participants and aimed to match participant preferences for dates and times of the group meetings. The five groups met weekly for 8 weeks at UCLH. Each session lasted approximately 90 min. The theory-based intervention has been previously described.15 In brief, it included advice on healthy eating, physical activity, management of triggers of unhealthy behaviours and behavioural relapse prevention. A dietitian (DAK) trained on the programme facilitated the group sessions following a standardised and scripted protocol. An extra trained provider (psychologist or dietitian) attended the meetings of the four groups to aid with facilitation but did not participate in the discussion. DAK was the only facilitator in the last group because of last minute cancellations. The participants in the fourth and final round of randomisation were split into two small intervention groups for convenience purposes. A participant from the control group who had completed the study was invited to participate in the last group (final n=4 in group 5) to enhance the group experience but was not included in the analysis. There were no other modifications. The completed Consolidated Standards of Reporting Trials (CONSORT)17 and Template for Intervention Description and Replication (TIDieR) checklists18 are available in online supplementary appendices S1 and S2, respectively.

Care as usual

Participants in the control arm were offered usual care. After the final follow-up, they received a booklet with healthy lifestyle advice for cancer survivors.19

Outcomes

Recruitment rates were calculated separately for each strategy and site. We adapted an existing framework of hierarchical recruitment barriers (availability by disease characteristics, eligibility, physician triage, trial discussion, interest, consent, and enrolment)20 to describe the recruitment process. In contrast with the original framework, the category ‘interest’ preceded that of ‘trial discussed’ to fit the current recruitment process. Participants who were introduced to the study and decided not to enrol completed a 25-item investigator-designed survey21 about barriers to participation. Eight UCLH clinicians were interviewed about their views on study recruitment using a semistructured protocol over phone or face-to-face (online supplementary appendix S3). Participants attended a 90-min baseline site visit with a trained researcher (DAK) to complete their measurements and questionnaires. The visit was repeated at 8 and 24 weeks with MM and DAK, respectively. All intervention sessions were audiotaped. RJB attended one intervention session and one study assessment and scored them against a predefined checklist. Engaged intervention-arm participants completed and posted an 18-item programme evaluation questionnaire.22 Only two follow-up qualitative interviews with intervention participants were performed at study completion, as the data from the open-ended feedback questionnaire were deemed sufficient.

Statistical and qualitative analysis

Despite the pilot nature of the study, a sample size of 32 participants per arm was estimated for examining recruitment, adherence, and retention rates. The study would be deemed feasible if the lower 95% CIs for recruitment, adherence and retention rates were at least 15%, 60%, and 60%, respectively.15 Primary outcomes are reported in proportions with 95% CIs. Descriptive statistics are reported for continuous variables. Categorical variables are summarised using frequencies and percentages. The interviews with clinicians lasted 10 min on average, were digitally recorded, transcribed verbatim by a professional company and checked for accuracy. Given the structured interview and short replies, data were analysed with content analysis using NVivo V.10 (QSR International, 2014) software. The open-ended questions were analysed using manifest content analysis23 in Microsoft Office Excel V.2011. This process involved determining the frequency of words and content in the text.

Results

Recruitment took place over a period of 27 and 18 weeks (April 2015–December 2015) at UCLH and Barts Health, respectively (figure S1 of online supplementary appendix S3). The difference in recruitment period between sites was primarily explained by substantial delay of NHS Research and Development management approval at Barts Health. Among the first 64 eligible participants approached, 20 consented to participate, leading to rejection of the null hypothesis that recruitment would be ≤15%. Therefore, recruitment continued for enrolling the projected sample of 64 participants but stopped after enrolling 60 participants due to resource constraints. Out of 296 potentially eligible participants, 20.3% (95% CI 15.7% to 24.9%) enrolled in the study. Among screened participants, rates of consent were similar for the face-to-face recruitment at the two recruitment sites but lower for the mail-out (tables S1 and S2 of online supplementary appendix S3). Reasons for non-participation were documented for 36.7% (n=83) of those who were potentially eligible but did not consent and 90.2% of those that were approached. Inconvenience to everyday life (78%) and transport to trial site (63%) were the main barriers to participation, with further barriers detailed in table 1 and less frequent barriers in table S3 of online supplementary appendix 3. The CONSORT flow diagram shows the progress through the trial stages (figure 1).
Table 1

Percentage of each barrier to participation with SE among eligible survivors who declined participation (n=83)

Barrier to participation% (SE)
Inconvenient to everyday life78.3 (4.5)
Transport or distance to trial site62.7 (5.3)
Feelings of uncertainty15.7 (4.0)
Lack of family support15.7 (4.0)
The design of the study is too difficult to understand or too binding15.7 (4.0)
Trial or treatment has no benefits15.7 (4.0)
Other: feeling physically unwell14.5 (3.9)
Preference for other treatment (eg, Weight Watchers)13.3 (3.7)
Increased anxiety12.1 (3.6)
Quality of life might be reduced12.1 (3.6)
Trial or treatment does not offer best option12.1 (3.6)
Trial setting9.6 (3.2)
Uncomfortable with experimentation9.6 (3.2)
Do not want to lose control of decision-making7.2 (2.8)
General unease with research process7.2 (2.8)
Other: does not like to discuss in groups6.0 (2.6)
Belief that doctor should make decisions4.8 (2.4)
Dislike idea of randomisation4.8 (2.4)
Fear or mistrust of research or researchers4.8 (2.4)
Other: family health issues4.8 (2.4)
Assignment to control group3.6 (2.1)
Potential side effects3.6 (2.1)
Trials not appropriate for serious disease2.4 (1.7)
Figure 1

Consolidated Standards of Reporting Trials diagram of the trial with framework on barriers to participation in the exclusion box. wk, week.

Consolidated Standards of Reporting Trials diagram of the trial with framework on barriers to participation in the exclusion box. wk, week. Percentage of each barrier to participation with SE among eligible survivors who declined participation (n=83)

Clinicians’ views on recruitment

Clinicians were supportive of the study and did not have particular concerns about introducing the study to patients. They felt the study might be beneficial to patients, but they believed travelling and commitment would be the main barriers for recruitment. They deemed the recruitment strategy highly effective, with potentially eligible patients being flagged prior to the clinic, researchers being present and reminding them about approaching patients, and through the existence of a separate space for study recruitment in the clinic. These strategies minimised additional clinician workload. Clinicians did not anticipate adverse events from the intervention or changes in their relationship with the patients. The framing and content of such an intervention was also highlighted as a potential barrier to recruitment. In particular, approaching patients in a non-discriminatory way was deemed to enhance recruitment. Furthermore, framing of its content as a lifestyle programme was thought to be superior to a weight loss programme, strict diet regime or educational programme.

Sample characteristics

Participant characteristics at baseline are shown in table 2. Women were on average (±SD) 62.1±8.3 years old, white (67%), married (53%), 1.2±1.0 years from diagnosis, with a BMI of 28.0±6.3 kg/m2. They were diagnosed mostly with stage IA (49%), type 1 (82%) endometrial cancer.
Table 2

DEUS pilot trial baseline participant characteristics

CharacteristicShape-Up (n=25)Care as usual (n=24)Total
Age, mean (SD)62.6 (9.0)61.5 (7.7)62.1 (8.3)
Race
 White17 (68)16 (67)33 (67)
 Asian4 (16)5 (21)9 (18)
 Other4 (16)3 (12)7 (14)
Living arrangement
 Own outright/mortgage17 (68)15 (63)32 (65)
 Rent8 (30)9 (38)17 (35)
Marital status
 Married/living with partner/civil partnership12 (48)15 (63)27 (55)
 Separated/divorced7 (28)3 (12)10 (20)
 Widowed/single6 (24)6 (25)12 (24)
Education
 Degree/higher degree/higher education below degree level11 (44)12 (50)23 (47)
 Secondary education11 (44)10 (42)21 (42)
 No formal qualifications3 (12)2 (8)5 (10)
Employment
 Full time/self-employed9 (36)11 (46)20 (41)
 Part time/other6 (24)2 (8)8 (16)
 Retired10 (40)11 (46)21 (43)
Smoking
 Current2 (8)2 (8)4 (8)
 Former4 (16)5 (21)9 (18)
IMD (quintile)
 1 (most deprived)5 (20)4 (17)9 (18)
 29 (36)6 (25)15 (31)
 34 (16)7 (29)11 (22)
 43 (12)3 (13)6 (12)
 5 (least deprived)4 (16)4 (17)8 (16)
Time since diagnosis in months, mean (SD)19.2 (11.2)21.4 (11.3)20.3 (11.2)
Time since completion of primary treatment in months, mean (SD)17.1 (11.2)18.5 (11.7)17.8 (11.3)
Surgery25 (100)24 (100)49 (100)
Chemotherapy treatment3 (12)5 (21)8 (16)
External beam radiotherapy6 (24)12 (50)18 (37)
Brachytherapy11 (44)13 (54)24 (49)
Cancer stage
 IA11 (44)13 (54)24 (49)
 IB11 (44)6 (25)17 (35)
 II2 (8)3 (13)5 (10)
 IIIA1 (4)2 (8)3 (6)
Cancer grade
 16 (24)7 (29)13 (27)
 213 (52)9 (38)22 (45)
 36 (24)8 (33)14 (29)
Histology
 Endometrioid adenocarcinoma21 (84)19 (79)40 (82)
 Serous carcinoma1 (4)3 (13)4 (8)
 Mixed carcinoma1 (4)0 (0)1 (2)
 Serous surface papillary carcinoma0 (0)1 (4)1 (2)
 Carcinosarcoma2 (8)0 (0)2 (4)
 Adenosquamous carcinoma0 (0)1 (4)1 (2)
Histological type
 Type I21 (84)19 (79)40 (82)
 Type II4 (16)5 (21)9 (18)
Charlson Comorbidity Index
 218 (75)21 (84)39 (80)
 36 (25)4 (16)10 (20)
WHO performance status
 020 (83)20 (80)40 (82)
 13 (13)5 (20)8 (16)
 21 (4)0 (0)1 (2)
Selected comorbidities
 Diabetes3 (12)4 (17)7 (14)
 Hypertension6 (24)7 (29)13 (27)
 Dyslipidaemia3 (12)3 (13)6 (12)
 Asthma1 (4)2 (8)3 (6)
 Osteoporosis2 (8)4 (17)6 (12)
 Weight, mean kg (SD)69.8 (14.8)71.9 (15.2)70.9 (14.9)
 BMI, mean kg/m2 (SD)27.3 (6.5)28.8 (6.1)28.0 (6.3)
 BMI, median kg/m2 (IQR)26.2 (24.3)26.9 (8.6)26.8 (6l.4)
 % Fat, mean (SD)35.3 (7.7)36.9 (6.3)36.1 (7.0)

Percentages might not add to 100 due to rounding.

Data are presented as n (%) unless otherwise specified.

Body composition data for usual care n=23.

BMI, body mass index; DEUS, Diet and Exercise in Uterine Cancer Survivors; IMD, index of multiple deprivation.

DEUS pilot trial baseline participant characteristics Percentages might not add to 100 due to rounding. Data are presented as n (%) unless otherwise specified. Body composition data for usual care n=23. BMI, body mass index; DEUS, Diet and Exercise in Uterine Cancer Survivors; IMD, index of multiple deprivation.

Adherence

Out of 26 participants in the intervention arm, 21 (81%; 95% CI 66% to 96%) engaged and 20 (77%; 95% CI 61% to 93%) adhered to the intervention, based on our predetermined criteria.15 The lower CI was above 60% indicating feasibility. The percentage of participants who attended zero, five, six, seven, and eight (all) sessions was 15%, 8%, 12%, 35%, and 15%, respectively. The mean overall attendance of sessions was 63% (95% CI 49% to 77%). The mean attendance rates of those who engaged and those who adhered were 79% (95% CI 70% to 88%) and 82% (95% CI 74% to 89%), respectively. Reasons for not commencing the intervention (ie, attendance of zero sessions) included inconvenience to everyday life (n=1), family commitments (n=1), lack of perceived benefit (n=1) or travel burden (n=1). The remaining two dropouts occurred in the first two sessions due to programme content and travelling abroad. Absence from the group sessions among adhered participants were mostly of practical nature, with details available in online supplementary appendix S3.

Programme satisfaction

Eighteen participants randomised to the intervention group who adhered provided feedback for the programme. They scored the programme highly with 44% and 39% reporting that it met or exceeded their expectations, respectively. All aspects of the programme were scored highly (table 3). Additionally, most participants ranked self-monitoring, setting specific, measurable, achievable, relevant, and time-specific goals, and social support as either very or somewhat helpful in making dietary and physical activity changes (table 4). In contrast, the responses for self-incentives were mixed with 28% of participants rating this technique as unhelpful.
Table 3

Percentage programme satisfaction (n=18)

How much did you like the…Dislike (%)Neither like or dislike (%)Like (%)
Organisation of the sessions100
Length of the programme1189
Dates of the programme61778
Length of the sessions100
Training location100
Group format100
Peer-education format694
Group discussion100
Cultural sensitivity of the facilitator100
Facilitator’s knowledge of materials694
Facilitator’s preparedness100
Time used effectively by facilitator100
Attractiveness of the booklet61778
Overall design of the booklet1784
Wording of the booklet2277
Volume of the booklet172261
Durability of the booklet1783
Table 4

Helpfulness of the main behaviour change techniques for dietary and physical activity changes (n=18)

Unhelpful (%)Neither helpful or unhelpful (%)Helpful (%)
When trying to make diet changes, how helpful did you find monitoring yourself using diaries?100
When trying to make physical activity changes, how helpful did you find monitoring yourself using diaries?6%688
When trying to make diet changes, how helpful did you find putting SMART goals? 1188
When trying to make physical activity changes, how helpful did you find putting SMART goals?1189
When trying to make diet changes, how helpful did you find rewarding yourself?28%3339
When trying to make physical activity changes, how helpful did you find rewarding yourself?28%3934
When trying to make diet changes, how helpful did you find the peer-education nature of the sessions?695
When trying to make physical activity changes, how helpful did you find the peer-education nature of the sessions?1783

SMART, specific, measurable, achievable, relevant, and time specific

Percentage programme satisfaction (n=18) Helpfulness of the main behaviour change techniques for dietary and physical activity changes (n=18) SMART, specific, measurable, achievable, relevant, and time specific A range of topics were regarded as most useful (figure S2 of online supplementary appendix S3). Among them, most participants agreed that the sections about keeping an eye on portion sizes, food labelling and internal triggers were the most useful. Others mentioned self-incentives, internal and external triggers and getting a healthier balance of foods to be the least useful topics (figure S3 of online supplementary appendix 3). For example, one participant mentioned: I also did not understand the concept of the rewards—better health should be its own reward (Participant in group 4). Suggestions for additions to the programme were primarily focused on physical activity, such as provision of relevant digital video discs, physical activity during the programme sessions and diaries to report physical activity and sedentary behaviour in more detail. Most participants did not consider that topics should be eliminated from the programme. Similar feedback was provided for the booklet; most participants did not suggest changes while a few suggested design changes. Further suggestions included the addition of follow-up support and a preference for a larger group (mentioned by participants in smaller groups) to boost the peer-education component. Peer support of the group, both the focus of the programme and their own interest in health promotion, the feeling of giving back to the care system, the facilitators and the doctor’s referral to the programme facilitated study participation. In contrast, most did not report factors discouraging them to participate, but some mentioned inconvenience to everyday life, self-monitoring, and identification as a cancer survivor. Regarding the trial procedures, two participants mentioned their difficulty recalling and quantifying their diet and physical activity. Excellent fidelity to the protocol for both the group sessions (85%) and the assessments (100%) was demonstrated in the study auditing.

Retention

Retention rate was 92% (95% CI 85% to 100%), with 24/28 (86%; 95% CI 73% to 99%) and 25/26 (96%; 95% CI 89% to 100%) eligible participants in the control and intervention arm completing all assessments, respectively (p=0.61 for difference between proportions). This indicated an absence of attrition bias and the rejection of the null hypothesis that retention rate would be less than 60%.

Adverse events and control arm contamination

No intervention-related adverse events or unintended consequences were reported. Adverse events unrelated to the intervention and reasons for control arm contamination are detailed in the online supplementary appendix S3.

Discussion

This is the first pilot study of a health behaviour change intervention in ECS in the UK to demonstrate feasibility in terms of recruitment, adherence, and retention. The collaboration of the clinical and research team led to an efficient recruitment process. Participants rated the programme highly and provided rich feedback for refinement. Consistent with the literature24 and the qualitative findings,7 the DEUS pilot study aimed to minimise accrual barriers by enrolling survivors within the ‘teachable moment’ period, capitalising on the endorsement of the study from survivors’ clinicians, using a strong behaviour theory-based design and ensuring standardised delivery of the intervention. These study strengths were also reflected in the reported factors associated with programme involvement. Furthermore, the frameworks for reporting barriers to participation20 21 provided a comprehensive understanding of these barriers and can be a valuable resource to understand barriers in for future trials.25 Limitations of the study include the small sample size, recruitment from only two London-based sites, and generalisability of the recruited sample, as sociodemographic data from decliners were missing. The relatively low median BMI of participants compared with epidemiological studies26 indicates healthy volunteer effect biases. The wide socioeconomic and demographic differences of the population pools of the two hospitals27 and the similar recruitment rates at both sites were reassuring and suggest these factors should not impact recruitment and retention. The focus of the study on healthy lifestyle changes rather than weight loss was postulated to increase uptake and acceptability of the programme.7 The overall recruitment estimate was similar or somewhat higher than that in other lifestyle intervention trials, although differences in recruitment strategies, eligibility criteria, cancer site, programme length and intensity do not allow for direct comparisons. The group-based, 6-month Survivors of Uterine Cancer Empowered by Exercise and Healthy Diet (SUCCEED) intervention had a 19% recruitment rate using mail-out.12 A 12-week group-based physical activity intervention recruited 20% of the eligible ECS through fliers and telephone recruitment.28 Similar to DEUS, a more intensive lifestyle intervention in UK breast cancer survivors had a mail-out rate of 17%.29 While removing the transport and time barriers would theoretically improve recruitment rates, USA home-based lifestyle interventions recruiting cancer survivors from registries have shown much smaller recruitment rates (5.7%) with women, younger, white survivors, and those closer to their cancer diagnosis more likely to enrol.30 The observed adherence was lower compared with the weight loss SUCCEED intervention (84.1%) comprising 16 group sessions12 but similar to that of a group-based 12-week physical activity intervention.28 While this might indicate that survivors are more committed in weight loss programmes compared with healthy lifestyle programmes, the main reported reasons regarding non-attendance in the current study were around practicalities and life commitments rather than disengagement with the programme. Sending a standardised email to non-attendees about topics covered in the missed session and preparation for the next session helped maintain their engagement. Having a specific research room and two committed researchers in clinic facilitated recruitment. Screening participants using electronic forms and implementing further prerandomisation eligibility checks from medical notes could minimise randomisation of ineligible participants. The recruitment rate, while similar between the two sites, was lower in the clinician-endorsed mail-out, indicating the higher effectiveness of the first approach that needs to be balanced with its higher resource requirements in larger trials. Practical reasons rendered intervention adherence acceptable but not optimal. The difficulty of trying to arrange a weekly group meeting with approximately eight people was evident, although a range of potential times was offered to participants and involved working around the logistics to find the most convenient date. Given the wide variability of participants’ availability, simultaneous offers of a group on a weekday early evening or Saturday morning facilitated engagement in groups 2 and 3. In future studies, larger groups will be possible by unblinding investigators after enough participants are allocated to each trial arm to run two groups. Opting for the group-based and face-to-face design aimed to meet survivors’ preferences7 but was in contrast with some previous studies reporting proximity as a particular barrier in this population.24 The lack of dropouts after the second group session indicated the overall acceptability of the intervention and the favourable rating of most programme aspects provides confidence that only minor content adaptations are needed before testing the study in a large trial. As multiple facilitators will deliver the intervention in a pragmatic setting, future large-scale trials should also measure differences in intervention delivery between various facilitators. Inconvenience and transport were the main barriers to accrual in the current study. Increasing reach might be more feasible with blended designs of group meetings and remote intervention delivery, especially as home-based interventions have typically experienced much lower recruitment rates compared with group-based interventions. In the current programme, even those who adhered mentioned convenience reasons as discouraging participation but the peer support as encouraging. This might suggest delivering some sessions in person and others remotely, potentially through web or mobile technology. A pilot weight loss study with endometrial and breast cancer survivors delivered via a mobile application has shown promising results in a pre–post design.31 However, further research on mobile applications for weight management is needed, as most lack evidence-based behaviour change techniques, involvement of healthcare professionals, and scientific evaluation.32 In conclusion, this self-help lifestyle intervention trial was feasible in terms of recruitment, adherence and retention. Scaling the trial will require close monitoring of recruitment and attempts should be made to reduce the burden on participants. Further qualitative work could inform a blended in-person and remote design to enhance adherence while retaining the valued peer support. This should be considered before proceeding to a definitive trial. Overall, the lessons learnt from this pilot should inform the design of future studies in this area.

Full protocol availability

The full protocol of the study has been previously published15 and it can also be found in the online supplementary appendix 4.
  27 in total

1.  Cardiovascular disease is the leading cause of death among endometrial cancer patients.

Authors:  Kristy K Ward; Nina R Shah; Cheryl C Saenz; Michael T McHale; Edwin A Alvarez; Steven C Plaxe
Journal:  Gynecol Oncol       Date:  2012-04-13       Impact factor: 5.482

Review 2.  Lifestyle interventions in cancer survivors: designing programs that meet the needs of this vulnerable and growing population.

Authors:  Valeda B Stull; Denise C Snyder; Wendy Demark-Wahnefried
Journal:  J Nutr       Date:  2007-01       Impact factor: 4.798

Review 3.  Barriers to participation in clinical trials of cancer: a meta-analysis and systematic review of patient-reported factors.

Authors:  Edward J Mills; Dugald Seely; Beth Rachlis; Lauren Griffith; Ping Wu; Kumanan Wilson; Peter Ellis; James R Wright
Journal:  Lancet Oncol       Date:  2006-02       Impact factor: 41.316

4.  The National Cancer Institute-American Society of Clinical Oncology Cancer Trial Accrual Symposium: summary and recommendations.

Authors:  Andrea M Denicoff; Worta McCaskill-Stevens; Stephen S Grubbs; Suanna S Bruinooge; Robert L Comis; Peggy Devine; David M Dilts; Michelle E Duff; Jean G Ford; Steven Joffe; Lidia Schapira; Kevin P Weinfurt; Margo Michaels; Derek Raghavan; Ellen S Richmond; Robin Zon; Terrance L Albrecht; Michael A Bookman; Afshin Dowlati; Rebecca A Enos; Mona N Fouad; Marjorie Good; William J Hicks; Patrick J Loehrer; Alan P Lyss; Steven N Wolff; Debra M Wujcik; Neal J Meropol
Journal:  J Oncol Pract       Date:  2013-10-15       Impact factor: 3.840

5.  Diet and exercise in uterine cancer survivors (DEUS pilot) - piloting a healthy eating and physical activity program: study protocol for a randomized controlled trial.

Authors:  Dimitrios A Koutoukidis; Rebecca J Beeken; Ranjit Manchanda; Matthew Burnell; M Tish Knobf; Anne Lanceley
Journal:  Trials       Date:  2016-03-10       Impact factor: 2.279

Review 6.  A systematic review and meta-analysis of social cognitive theory-based physical activity and/or nutrition behavior change interventions for cancer survivors.

Authors:  Fiona G Stacey; Erica L James; Kathy Chapman; Kerry S Courneya; David R Lubans
Journal:  J Cancer Surviv       Date:  2014-11-29       Impact factor: 4.442

7.  Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-years for 32 Cancer Groups, 1990 to 2015: A Systematic Analysis for the Global Burden of Disease Study.

Authors:  Christina Fitzmaurice; Christine Allen; Ryan M Barber; Lars Barregard; Zulfiqar A Bhutta; Hermann Brenner; Daniel J Dicker; Odgerel Chimed-Orchir; Rakhi Dandona; Lalit Dandona; Tom Fleming; Mohammad H Forouzanfar; Jamie Hancock; Roderick J Hay; Rachel Hunter-Merrill; Chantal Huynh; H Dean Hosgood; Catherine O Johnson; Jost B Jonas; Jagdish Khubchandani; G Anil Kumar; Michael Kutz; Qing Lan; Heidi J Larson; Xiaofeng Liang; Stephen S Lim; Alan D Lopez; Michael F MacIntyre; Laurie Marczak; Neal Marquez; Ali H Mokdad; Christine Pinho; Farshad Pourmalek; Joshua A Salomon; Juan Ramon Sanabria; Logan Sandar; Benn Sartorius; Stephen M Schwartz; Katya A Shackelford; Kenji Shibuya; Jeff Stanaway; Caitlyn Steiner; Jiandong Sun; Ken Takahashi; Stein Emil Vollset; Theo Vos; Joseph A Wagner; Haidong Wang; Ronny Westerman; Hajo Zeeb; Leo Zoeckler; Foad Abd-Allah; Muktar Beshir Ahmed; Samer Alabed; Noore K Alam; Saleh Fahed Aldhahri; Girma Alem; Mulubirhan Assefa Alemayohu; Raghib Ali; Rajaa Al-Raddadi; Azmeraw Amare; Yaw Amoako; Al Artaman; Hamid Asayesh; Niguse Atnafu; Ashish Awasthi; Huda Ba Saleem; Aleksandra Barac; Neeraj Bedi; Isabela Bensenor; Adugnaw Berhane; Eduardo Bernabé; Balem Betsu; Agnes Binagwaho; Dube Boneya; Ismael Campos-Nonato; Carlos Castañeda-Orjuela; Ferrán Catalá-López; Peggy Chiang; Chioma Chibueze; Abdulaal Chitheer; Jee-Young Choi; Benjamin Cowie; Solomon Damtew; José das Neves; Suhojit Dey; Samath Dharmaratne; Preet Dhillon; Eric Ding; Tim Driscoll; Donatus Ekwueme; Aman Yesuf Endries; Maryam Farvid; Farshad Farzadfar; Joao Fernandes; Florian Fischer; Tsegaye Tewelde G/Hiwot; Alemseged Gebru; Sameer Gopalani; Alemayehu Hailu; Masako Horino; Nobuyuki Horita; Abdullatif Husseini; Inge Huybrechts; Manami Inoue; Farhad Islami; Mihajlo Jakovljevic; Spencer James; Mehdi Javanbakht; Sun Ha Jee; Amir Kasaeian; Muktar Sano Kedir; Yousef S Khader; Young-Ho Khang; Daniel Kim; James Leigh; Shai Linn; Raimundas Lunevicius; Hassan Magdy Abd El Razek; Reza Malekzadeh; Deborah Carvalho Malta; Wagner Marcenes; Desalegn Markos; Yohannes A Melaku; Kidanu G Meles; Walter Mendoza; Desalegn Tadese Mengiste; Tuomo J Meretoja; Ted R Miller; Karzan Abdulmuhsin Mohammad; Alireza Mohammadi; Shafiu Mohammed; Maziar Moradi-Lakeh; Gabriele Nagel; Devina Nand; Quyen Le Nguyen; Sandra Nolte; Felix A Ogbo; Kelechi E Oladimeji; Eyal Oren; Mahesh Pa; Eun-Kee Park; David M Pereira; Dietrich Plass; Mostafa Qorbani; Amir Radfar; Anwar Rafay; Mahfuzar Rahman; Saleem M Rana; Kjetil Søreide; Maheswar Satpathy; Monika Sawhney; Sadaf G Sepanlou; Masood Ali Shaikh; Jun She; Ivy Shiue; Hirbo Roba Shore; Mark G Shrime; Samuel So; Samir Soneji; Vasiliki Stathopoulou; Konstantinos Stroumpoulis; Muawiyyah Babale Sufiyan; Bryan L Sykes; Rafael Tabarés-Seisdedos; Fentaw Tadese; Bemnet Amare Tedla; Gizachew Assefa Tessema; J S Thakur; Bach Xuan Tran; Kingsley Nnanna Ukwaja; Benjamin S Chudi Uzochukwu; Vasiliy Victorovich Vlassov; Elisabete Weiderpass; Mamo Wubshet Terefe; Henock Gebremedhin Yebyo; Hassen Hamid Yimam; Naohiro Yonemoto; Mustafa Z Younis; Chuanhua Yu; Zoubida Zaidi; Maysaa El Sayed Zaki; Zerihun Menlkalew Zenebe; Christopher J L Murray; Mohsen Naghavi
Journal:  JAMA Oncol       Date:  2017-04-01       Impact factor: 31.777

8.  Removing barriers to participation in clinical trials, a conceptual framework and retrospective chart review study.

Authors:  Norma F Kanarek; Marty S Kanarek; Dare Olatoye; Michael A Carducci
Journal:  Trials       Date:  2012-12-10       Impact factor: 2.279

9.  Mobile Apps for Weight Management: A Scoping Review.

Authors:  Jordan Rivera; Amy McPherson; Jill Hamilton; Catherine Birken; Michael Coons; Sindoora Iyer; Arnav Agarwal; Chitra Lalloo; Jennifer Stinson
Journal:  JMIR Mhealth Uhealth       Date:  2016-07-26       Impact factor: 4.773

10.  CONSORT 2010 statement: extension to randomised pilot and feasibility trials.

Authors:  Sandra M Eldridge; Claire L Chan; Michael J Campbell; Christine M Bond; Sally Hopewell; Lehana Thabane; Gillian A Lancaster
Journal:  Pilot Feasibility Stud       Date:  2016-10-21
View more
  9 in total

1.  Perceptions of eHealth-Enabled Physical Activity Interventions Among Cancer Survivors: Mixed Methods Study.

Authors:  Ciaran Haberlin; Dearbhaile M O' Donnell; Jonathan Moran; Julie Broderick
Journal:  JMIR Cancer       Date:  2020-04-28

2.  Phase II randomised control feasibility trial of a nutrition and physical activity intervention after radical prostatectomy for prostate cancer.

Authors:  Lucy E Hackshaw-McGeagh; Chris Penfold; Ellie Shingler; Luke A Robles; Claire M Perks; Jeff M P Holly; Edward Rowe; Anthony Koupparis; Amit Bahl; Raj Persad; Constance Shiridzinomwa; Lyndsey Johnson; Kalina M Biernacka; Aleksandra Frankow; Jayne V Woodside; Sarah Gilchrist; Jon Oxley; Paul Abrams; J Athene Lane; Richard M Martin
Journal:  BMJ Open       Date:  2019-11-06       Impact factor: 2.692

3.  Impact of a Tailored Nutrition and Lifestyle Intervention for Overweight Cancer Survivors on Dietary Patterns, Physical Activity, Quality of Life, and Cardiometabolic Profiles.

Authors:  Colleen K Spees; Ashlea C Braun; Emily B Hill; Elizabeth M Grainger; James Portner; Gregory S Young; Matthew D Kleinhenz; Chureeporn Chitchumroonchokchai; Steven K Clinton
Journal:  J Oncol       Date:  2019-11-21       Impact factor: 4.375

4.  Improvements in strength and agility measures of functional fitness following a telehealth-delivered home-based exercise intervention in endometrial cancer survivors.

Authors:  Jessica S Gorzelitz; Stefanie Stoller; Erin Costanzo; Ronald Gangnon; Kelli Koltyn; Amy Trentham Dietz; Ryan J Spencer; Joanne Rash; Lisa Cadmus-Bertram
Journal:  Support Care Cancer       Date:  2021-07-25       Impact factor: 3.359

Review 5.  Interventions for weight reduction in obesity to improve survival in women with endometrial cancer.

Authors:  Sarah Kitson; Neil Ryan; Michelle L MacKintosh; Richard Edmondson; James Mn Duffy; Emma J Crosbie
Journal:  Cochrane Database Syst Rev       Date:  2018-02-01

6.  The Association of Dietary Patterns with High-Risk Human Papillomavirus Infection and Cervical Cancer: A Cross-Sectional Study in Italy.

Authors:  Martina Barchitta; Andrea Maugeri; Annalisa Quattrocchi; Ottavia Agrifoglio; Aurora Scalisi; Antonella Agodi
Journal:  Nutrients       Date:  2018-04-11       Impact factor: 5.717

7.  Use of intervention mapping to adapt a health behavior change intervention for endometrial cancer survivors: the shape-up following cancer treatment program.

Authors:  Dimitrios A Koutoukidis; Sonia Lopes; Lou Atkins; Helen Croker; M Tish Knobf; Anne Lanceley; Rebecca J Beeken
Journal:  BMC Public Health       Date:  2018-03-27       Impact factor: 3.295

8.  Breast, Prostate, and Colorectal Cancer Survivors' Experiences of Using Publicly Available Physical Activity Mobile Apps: Qualitative Study.

Authors:  Anna L Roberts; Henry Ww Potts; Dimitrios A Koutoukidis; Lee Smith; Abigail Fisher
Journal:  JMIR Mhealth Uhealth       Date:  2019-01-04       Impact factor: 4.773

9.  The adapted Zelen was a feasible design to trial exercise in myeloma survivors.

Authors:  Joanne Land; Orla McCourt; Malgorzata Heinrich; Rebecca J Beeken; Dimitrios A Koutoukidis; Bruce Paton; Kwee Yong; Allan Hackshaw; Abigail Fisher
Journal:  J Clin Epidemiol       Date:  2020-04-11       Impact factor: 6.437

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.